US Patent

US11007198 — ErbB/BTK inhibitors

Composition of Matter · Assigned to Dizal Jiangsu Pharmaceutical Co Ltd · Expires 2039-01-28 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit certain proteins, specifically ErbBs and BTK, and their pharmaceutical compositions for treating diseases associated with these proteins.

USPTO Abstract

Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

Drugs covered by this patent

Patent Metadata

Patent number: US11007198
Jurisdiction: US
Classification: Composition of Matter
Expires: 2039-01-28
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dizal Jiangsu Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.